
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Breast-feeding infants whose mothers are on anti-epileptic drug monotherapy do not appear to have an increased risk of cognitive impairment at age 2, according to research presented this week at the annual meeting of the American Academy of Neurology in Chicago.






